CRISPR Therapeutics Q2 2026: CASGEVY Revenue Surges to $76M, Cash Runway Extended Past 24 Months

summarizeSummary

CRISPR Therapeutics posted Q2 2026 results highlighted by $76M in CASGEVY revenue, a narrower net loss, and a robust $2.36B cash position. In July, the FDA broadened CASGEVY's label to include patients ages 2 and older.

check_boxKey Events · Earnings and Guidance · CRSP

• CASGEVY Revenue Hits $76M

  Driven by patient demand and label expansion, Q2 2026 CASGEVY revenue reached $76 million—a 151% increase year-over-year and 78% sequential growth.

• Net Loss Narrows to $91.2M

  The net loss improved to $91.2 million from $208.5 million in Q2 2025, aided by $10 million in collaboration revenue and lower acquired IPR&D costs.

• Cash Runway Extended Past 24 Months

  As of June 30, 2026, cash, cash equivalents, and marketable securities stood at $2.36 billion, following a $600 million convertible note offering completed in March 2026.

• FDA Expands CASGEVY Label to Ages 2+

  In July 2026, the FDA approved CASGEVY for patients ages 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia, significantly broadening the addressable market.

auto_awesomeAnalysis · CRSP · Life Sciences

A standout quarter for CRISPR Therapeutics saw CASGEVY revenue climb to $76 million, marking a 151% year-over-year leap and a 78% sequential gain. The balance sheet remains formidable at $2.36 billion in cash, reinforced by a $600 million convertible note offering in March, which pushes the cash runway beyond 24 months. The net loss contracted sharply to $91.2 million from $208.5 million a year ago, thanks to higher collaboration revenue and a drop in acquired IPR&D costs. Adding to the momentum, the FDA in July expanded CASGEVY's label to patients as young as 2 years old, unlocking a new patient segment. Meanwhile, the CFO and General Counsel adopted 10b5-1 trading plans—routine in nature but noteworthy given the stock's recent strength.